Rigel Pharmaceuticals
RIGL
Market Cap$390.52M
Close$
$-10.27
146.3% downside
Current Fair Value
146.3% downsideOvervalued by 146.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $390.52 Million |
|---|---|
| Enterprise Value | $400.42 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.44 |
| Beta | 0.95 |
| Outstanding Shares | 17,600,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 100.54 |
|---|---|
| PEG | -31.59 |
| Price to Sales | 2.77 |
| Price to Book Ratio | -22.17 |
| Enterprise Value to Revenue | 2.54 |
| Enterprise Value to EBIT | 39.33 |
| Enterprise Value to Net Income | 103 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -4.21 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez